|
US6710174B2
(en)
|
2001-09-13 |
2004-03-23 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of vascular endothelial growth factor receptor-1 expression
|
|
US6100071A
(en)
|
1996-05-07 |
2000-08-08 |
Genentech, Inc. |
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
|
|
US7087411B2
(en)
*
|
1999-06-08 |
2006-08-08 |
Regeneron Pharmaceuticals, Inc. |
Fusion protein capable of binding VEGF
|
|
US7070959B1
(en)
|
1999-06-08 |
2006-07-04 |
Regeneron Pharmaceuticals, Inc. |
Modified chimeric polypeptides with improved pharmacokinetic properties
|
|
US6833349B2
(en)
*
|
1999-06-08 |
2004-12-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating inflammatory skin diseases
|
|
US7396664B2
(en)
|
1999-06-08 |
2008-07-08 |
Regeneron Pharmaceuticals, Inc. |
VEGF-binding fusion proteins and nucleic acids encoding the same
|
|
JP4669984B2
(ja)
|
2001-01-19 |
2011-04-13 |
ベジェニクス リミテッド |
腫瘍画像化のターゲットとしてのＦ１ｔ４（ＶＥＧＦＲ−３）および抗腫瘍療法
|
|
US6734017B2
(en)
|
2001-09-28 |
2004-05-11 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of vascular endothelial growth factor receptor-2 expression
|
|
ES2362648T3
(es)
|
2002-05-04 |
2011-07-08 |
Acorda Therapeutics, Inc. |
Composiciones y métodos para promover la proyección neuronal.
|
|
DK1608685T3
(da)
|
2003-03-28 |
2007-06-11 |
Regeneron Pharma |
VEGF antagonister til behandlingen af diabetes
|
|
EP3211084B1
(en)
|
2003-05-16 |
2019-03-27 |
Acorda Therapeutics, Inc. |
Proteoglycan degrading mutants for treatment of cns
|
|
JP5399612B2
(ja)
*
|
2003-05-16 |
2014-01-29 |
アコーダ セラピューティクス、インク． |
Ｃｎｓを治療するための融合タンパク質
|
|
US7959914B2
(en)
|
2003-05-16 |
2011-06-14 |
Acorda Therapeutics, Inc. |
Methods of reducing extravasation of inflammatory cells
|
|
WO2004106378A2
(en)
*
|
2003-05-28 |
2004-12-09 |
Regeneron Pharmaceuticals, Inc. |
Method of treating corneal transplant rejection by using vegf antagonists
|
|
US7186699B2
(en)
|
2003-06-03 |
2007-03-06 |
Cell Genesys, Inc. |
Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
|
|
WO2004110490A2
(en)
*
|
2003-06-06 |
2004-12-23 |
Regeneron Pharmaceuticals, Inc. |
Use of vegf inhibitors for tumor regression
|
|
US7399612B2
(en)
|
2003-06-30 |
2008-07-15 |
Regeneron Pharmaceuticals, Inc. |
VEGF-binding fusion proteins and nucleic acids encoding the same
|
|
AR046510A1
(es)
*
|
2003-07-25 |
2005-12-14 |
Regeneron Pharma |
Composicion de un antagonista de vegf y un agente anti-proliferativo
|
|
US20050112061A1
(en)
*
|
2003-08-06 |
2005-05-26 |
Jocelyn Holash |
Use of a VEGF antagonist in combination with radiation therapy
|
|
AU2005244933B2
(en)
|
2004-05-18 |
2011-08-04 |
Acorda Therapeutics, Inc. |
Methods of purifying chondroitinase and stable formulations thereof
|
|
DK1767546T3
(da)
|
2004-06-08 |
2012-04-23 |
Chengdu Kanghong Biotechnologies Co Ltd |
Angiogenese-inhiberende kimært protein og dets anvendelse
|
|
MXPA06014421A
(es)
|
2004-06-10 |
2007-05-04 |
Regeneron Pharma |
Uso de inhibidores de vegf para el tratamiento de cancer humano.
|
|
CN1968709A
(zh)
*
|
2004-06-18 |
2007-05-23 |
瑞泽恩制药公司 |
用于治疗恶性胸腔积液的vegf抑制剂
|
|
CN1997386B
(zh)
|
2004-07-30 |
2012-05-30 |
瑞泽恩制药公司 |
通过阻断vegf介导的活性来治疗i型糖尿病的方法
|
|
EP1804835B9
(en)
*
|
2004-09-13 |
2010-09-29 |
Genzyme Corporation |
Multimeric constructs
|
|
FR2878749B1
(fr)
*
|
2004-12-03 |
2007-12-21 |
Aventis Pharma Sa |
Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
|
|
CA2621047A1
(en)
|
2005-02-02 |
2006-08-24 |
Regeneron Pharmaceuticals, Inc. |
Method of treating eye injury with local administration of a vegf inhibitor
|
|
US20060217311A1
(en)
|
2005-03-25 |
2006-09-28 |
Daniel Dix |
VEGF antagonist formulations
|
|
JP5189985B2
(ja)
|
2005-09-26 |
2013-04-24 |
アコーダ セラピューティクス、インク． |
コンドロイチナーゼａｂｃｉ変異体を用いた組成物およびその使用方法
|
|
CA2630839C
(en)
†
|
2005-12-16 |
2017-01-17 |
Regeneron Pharmaceuticals, Inc. |
Therapeutic methods for inhibiting tumor growth with dll4 antagonists
|
|
FR2895258B1
(fr)
|
2005-12-22 |
2008-03-21 |
Aventis Pharma Sa |
Combinaison comprenant de la combretastatine et des agents anticancereux
|
|
US8216575B2
(en)
|
2006-03-31 |
2012-07-10 |
Chengdu Kanghong Biotechnologies Co., Ltd. |
Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
|
|
CN100502945C
(zh)
*
|
2006-03-31 |
2009-06-24 |
成都康弘生物科技有限公司 |
Vegf受体融合蛋白在治疗眼睛疾病中的应用
|
|
PT2944306T
(pt)
|
2006-06-16 |
2021-02-15 |
Regeneron Pharma |
Formulações antagonistas de vegf adequadas para administração intravitreal
|
|
HUE028379T2
(en)
|
2006-09-29 |
2016-12-28 |
Oncomed Pharm Inc |
Preparations and procedures for the diagnosis and treatment of cancer
|
|
CA3086902C
(en)
|
2006-10-10 |
2021-11-09 |
Acorda Therapeutics, Inc. |
Compositions and methods of using chondroitinase abci mutants
|
|
FR2918279B1
(fr)
*
|
2007-07-05 |
2010-10-22 |
Aventis Pharma Sa |
Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
|
|
CN101575379B
(zh)
*
|
2008-05-09 |
2012-05-30 |
上海抗体药物国家工程研究中心有限公司 |
可溶性vegfr双功能融合受体、其制备方法及用途
|
|
ES2836948T3
(es)
|
2008-11-03 |
2021-06-28 |
Molecular Partners Ag |
Proteínas de unión que inhiben la interacción del receptor de VEGF-A
|
|
CN101838329A
(zh)
*
|
2009-03-18 |
2010-09-22 |
嘉和生物药业有限公司 |
抗血管新生融合蛋白
|
|
TR201818814T4
(tr)
|
2009-10-16 |
2019-01-21 |
Oncomed Pharm Inc |
Dll4 antagonist antikorlarının ve anti-hipertansif ajanların terapötik kombinasyonu ve kullanımı.
|
|
TWI510246B
(zh)
|
2010-04-30 |
2015-12-01 |
Molecular Partners Ag |
抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
|
|
ES2652508T3
(es)
|
2010-08-06 |
2018-02-02 |
Genzyme Corporation |
Composiciones de antagonistas de VEGF y sus usos
|
|
US20140080153A1
(en)
*
|
2011-01-07 |
2014-03-20 |
Chugai Seiyaku Kabushiki Kaisha |
Method for improving physical properties of antibody
|
|
EP3763379A1
(en)
|
2011-01-13 |
2021-01-13 |
Regeneron Pharmaceuticals, Inc. |
Use of a vegf antagonist to treat angiogenic eye disorders
|
|
JO3283B1
(ar)
|
2011-04-26 |
2018-09-16 |
Sanofi Sa |
تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
|
|
KR101397088B1
(ko)
|
2011-06-10 |
2014-05-19 |
강원대학교산학협력단 |
암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
|
|
JO3370B1
(ar)
*
|
2011-11-10 |
2019-03-13 |
Regeneron Pharma |
طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
|
|
JP6138815B2
(ja)
*
|
2011-12-01 |
2017-05-31 |
エーピー バイオサイエンシーズ， インコーポレイテッド |
補体経路およびｖｅｇｆ経路に対するタンパク質インヒビターおよびそれらの使用方法
|
|
CN103304668B
(zh)
*
|
2012-03-12 |
2015-10-28 |
江苏健德生物药业有限公司 |
Ultra-VEGF-trap免疫融合蛋白、其制备方法及其应用
|
|
PL2846836T3
(pl)
|
2012-05-07 |
2020-01-31 |
Allergan, Inc. |
Sposób leczenia amd u pacjentów opornych na terapię anty- vegf
|
|
WO2014006113A1
(en)
|
2012-07-03 |
2014-01-09 |
Sanofi |
Method of treating cancer by effective amounts of aflibercept
|
|
TW201438736A
(zh)
|
2012-11-14 |
2014-10-16 |
Regeneron Pharma |
以ｄｌｌ４拮抗劑治療卵巢癌之方法
|
|
HUE048687T2
(hu)
|
2013-02-18 |
2020-08-28 |
Vegenics Pty Ltd |
Ligandum kötõ molekulák és alkalmazásaik
|
|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
|
CN104193828B
(zh)
*
|
2013-09-12 |
2017-04-05 |
北京韩美药品有限公司 |
同时阻断her2和vegfr信号通路的重组融合蛋白
|
|
CN105960247A
(zh)
|
2013-11-05 |
2016-09-21 |
阿勒根公司 |
用抗vegf darpin治疗眼病的方法
|
|
CA2947456C
(en)
|
2014-05-12 |
2023-03-14 |
Formycon Ag |
Pre-filled plastic syringe containing a vegf antagonist
|
|
MX375557B
(es)
|
2014-07-18 |
2025-03-06 |
Sanofi Sa |
Método para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cáncer.
|
|
JP2016036322A
(ja)
*
|
2014-08-11 |
2016-03-22 |
日本化薬株式会社 |
血管新生因子と結合するキメラタンパク質
|
|
CA2970315C
(en)
|
2014-12-11 |
2023-08-22 |
Bayer Healthcare Llc |
Use of anti-vegf agents to treat lesions in macular degeneration patients
|
|
GB201503453D0
(en)
|
2015-03-01 |
2015-04-15 |
Jain Arjun |
Endothelin-1"sponge"
|
|
TWI870789B
(zh)
|
2015-08-04 |
2025-01-21 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
|
WO2017046140A1
(en)
|
2015-09-18 |
2017-03-23 |
Bayer Pharma Aktiengesellschaft |
Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
|
|
WO2017065559A1
(ko)
|
2015-10-15 |
2017-04-20 |
(주)알테오젠 |
Igg fc 도메인을 가지는 융합 단백질의 생산방법
|
|
KR101936049B1
(ko)
*
|
2015-10-15 |
2019-01-08 |
(주)알테오젠 |
IgG Fc 도메인을 가지는 융합 단백질의 생산방법
|
|
KR102854749B1
(ko)
|
2015-11-18 |
2025-09-04 |
에스아이오2 메디컬 프로덕츠, 엘엘씨 |
안과 제제용 제약 패키지
|
|
MX2018006171A
(es)
|
2015-11-18 |
2018-12-19 |
Formycon Ag |
Jeringa de plastico precargada que contiene un antagonista de vegf.
|
|
EP4556023A3
(en)
|
2015-11-18 |
2025-10-15 |
Formycon AG |
Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist
|
|
WO2017084616A1
(en)
*
|
2015-11-19 |
2017-05-26 |
Zhuhai Tairuishang Biopharm Ltd. |
Methods and compositions for binding vegf
|
|
KR102261636B1
(ko)
|
2015-12-03 |
2021-06-07 |
리제너론 파마슈티칼스 인코포레이티드 |
항-vegf로 치료된 연령-관련 황반 변성을 앓고 있는 환자에서의 임상 결과와 유전적 변이체를 연관시키는 방법
|
|
US10576128B2
(en)
|
2016-01-26 |
2020-03-03 |
Formycon Ag |
Liquid formulation of a VEGF antagonist
|
|
JPWO2018070390A1
(ja)
|
2016-10-12 |
2019-08-22 |
第一三共株式会社 |
抗ｒｏｂｏ４抗体と他剤を含む組成物
|
|
US11135266B2
(en)
|
2016-11-21 |
2021-10-05 |
Just-Evotec Biologics, Inc. |
Aflibercept formulations and uses thereof
|
|
WO2018215580A1
(en)
|
2017-05-24 |
2018-11-29 |
Formycon Ag |
Method for sterilizing prefilled plastic syringes containing a vegf antagonist
|
|
US20200237997A1
(en)
|
2017-05-24 |
2020-07-30 |
Formycon Ag |
Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
|
|
CA3063995A1
(en)
|
2017-05-24 |
2018-11-29 |
Sio2 Medical Products, Inc. |
Sterilizable pharmaceutical package for ophthalmic formulations
|
|
TW201904610A
(zh)
|
2017-06-14 |
2019-02-01 |
德商拜耳製藥公司 |
用於治療新生血管型青光眼之非抗體vegf拮抗劑
|
|
WO2019020777A1
(en)
|
2017-07-26 |
2019-01-31 |
Formycon Ag |
LIQUID FORMULATION OF A VEGF ANTAGONIST
|
|
CN111344410B
(zh)
|
2017-08-17 |
2023-09-15 |
济世易为生物有限公司 |
从宿主细胞半乳糖凝集素和其他污染物中纯化糖基化蛋白的方法
|
|
MY202872A
(en)
|
2017-11-20 |
2024-05-28 |
Just Evotec Biologics Inc |
Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
|
|
CR20200282A
(es)
|
2017-11-27 |
2021-02-18 |
4D Molecular Therapeutics Inc |
Cápsides variantes de virus adenoasociados y su uso para inhibir la angiogénesis
|
|
CN111465407A
(zh)
|
2017-11-30 |
2020-07-28 |
瑞泽恩制药公司 |
使用vegf拮抗剂治疗生血管性眼病
|
|
AU2018385394B2
(en)
*
|
2017-12-13 |
2024-05-02 |
Regeneron Pharmaceuticals, Inc. |
Devices and systems for chromatography column bed support management and related methods
|
|
BR112020015074A2
(pt)
*
|
2018-01-26 |
2020-12-08 |
The Regents Of The University Of California |
Métodos e composições para tratamento de transtornos angiogênicos com uso de agentes anti-vegf
|
|
BR112020017872A2
(pt)
|
2018-03-02 |
2020-12-22 |
Kodiak Sciences Inc. |
Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
|
|
JOP20200275A1
(ar)
|
2018-05-10 |
2020-11-02 |
Regeneron Pharma |
صيغ تحتوي على بروتين اندماج لمستقبلvegf مرتفعة التركيز
|
|
TW202016125A
(zh)
*
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
用於定量及調節蛋白質黏度之系統與方法
|
|
US11519020B2
(en)
|
2018-05-25 |
2022-12-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
|
|
CN111378044B
(zh)
|
2018-12-28 |
2022-07-15 |
长春金赛药业有限责任公司 |
抗体融合蛋白、制备方法及其应用
|
|
WO2020229584A1
(en)
|
2019-05-16 |
2020-11-19 |
Formycon Ag |
Method for reducing methionine oxidation in recombinant proteins
|
|
JP2022546082A
(ja)
|
2019-09-03 |
2022-11-02 |
アムジエン・インコーポレーテツド |
薬物送達のための注入デバイス及び注入デバイスのためのパッケージ
|
|
AU2020348947B2
(en)
|
2019-09-16 |
2025-11-27 |
Amgen Inc. |
Method for external sterilization of drug delivery device
|
|
CA3157509A1
(en)
|
2019-10-10 |
2021-04-15 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
|
CA3168512A1
(en)
|
2019-11-25 |
2021-06-03 |
Napoleone Ferrara |
Long-acting vegf inhibitors for intraocular neovascularization
|
|
MY193353A
(en)
*
|
2019-12-06 |
2022-10-06 |
Regeneron Pharma |
Anti-vegf protein compositions and methods for producing the same
|
|
MX2022006751A
(es)
|
2019-12-06 |
2022-08-19 |
Regeneron Pharma |
Minitrampas de vegf y metodos de uso de las mismas.
|
|
MX2022010177A
(es)
|
2020-02-24 |
2022-09-12 |
Amgen Inc |
Envases y sistemas para su uso durante la esterilizacion externa de dispositivos de administracion de farmacos.
|
|
CN115803009A
(zh)
|
2020-05-08 |
2023-03-14 |
瑞泽恩制药公司 |
用于治疗眼病和癌症的vegf阱和微阱及方法
|
|
WO2022231930A1
(en)
|
2021-04-26 |
2022-11-03 |
Celanese Eva Performance Polymers Llc |
Implantable device for sustained release of a macromolecular drug compound
|
|
EP4145456A1
(en)
|
2021-09-06 |
2023-03-08 |
Bayer AG |
Prediction of a change related to a macular fluid
|
|
WO2023092324A1
(zh)
|
2021-11-24 |
2023-06-01 |
苏州光度生物科技有限公司 |
多特异性配体结合分子及其应用
|
|
KR102764987B1
(ko)
|
2022-08-02 |
2025-02-12 |
주식회사 파노로스바이오사이언스 |
변형된 융합 단백질 및 이의 용도
|
|
KR20250065646A
(ko)
|
2022-09-16 |
2025-05-13 |
치루 파머수티컬 컴퍼니 리미티드 |
안정적인 고농도 자가완충식 약물 조성물
|
|
WO2025033876A1
(ko)
*
|
2023-08-04 |
2025-02-13 |
주식회사 파노로스바이오사이언스 |
변형된 융합 단백질과 scFv의 결합체 및 이의 용도
|
|
WO2025213011A1
(en)
|
2024-04-05 |
2025-10-09 |
Amgen Inc. |
Method of assessing stopper movement in a drug delivery device
|